Introduction to the 2026 CBIIC

The China BioMed Innovation and Investment Conference (CBIIC), as a premier platform fostering high-level dialogue between the pharmaceutical and investment industries, was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) in 2016. To promote the linkage between social capital and pharmaceutical innovation and improve the innovation capability of the pharmaceutical industry, the CBIIC focuses on China’s latest policies in the pharmaceutical industry, explores the new trends of global pharmaceutical R&D, and trends in the investment and financing circle. The CBIIC is built as an authoritative, comprehensive, professional, and international high-level platform for industry leaders, experts, scholars, domestic and foreign pharmaceutical innovation enterprises, and investors to discuss current trends of innovation and new strategies for investment and cooperation.On October 24–25, 2026, the 2026 CBIIC will convene once again. Focused on industrial transformation, frontier global pharmaceutical R&D trends, and evolving investment and financing dynamics, 2026 CBIIC will bring together leaders and experts from top leading research institutions, pharmaceutical companies, multinational corporations, and investment institutions at home and abroad, and conduct in-depth discussions on emerging trends in innovation-driven development, jointly explore new strategies for cross-border investment and collaboration, contributing insights to the resilient growth of the global pharmaceutical innovation ecosystem.